Like many of her Encanto costars, Angie Cepeda is a familiar face in Colombian film and television, though she's appeared in ...

My husband left me at 60 to have a baby with a younger woman. Here's what it taught me. Man's dishwasher discovery prompts thousands to check their own appliances With the penny going away, what ...

Madrigal Pharmaceuticals (MDGL) has quietly turned into one of the stronger performers in biotech, with the stock up roughly 77% over the past year as investors reassess its MASH treatment potential.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

Madrigal Pharmaceuticals (MDGL) is back on investors radar after Rezdiffra s early launch exceeded expectations, putting the MASH therapy on a path toward blockbuster level sales and reshaping the ...

In case you've faced some hurdles solving the clue, Hairstyle for Antonio Madrigal, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure ...

Madrigal (shoulder) cleared waivers and opted for free agency Thursday. Madrigal missed the full 2025 campaign after undergoing surgery in February to repair a fractured left shoulder. The infielder, ...

Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...